Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228273 | 0.86 | NAMPT (0.45) | NAMPTRAB9AMAPK1CYP2C19CYP3A4 | |
| SCHEMBL22606745 | 0.79 | DEGS1 (0.48) | NAMPTRAB9AHDAC1CYP17A1MAPK1 | |
| SCHEMBL24738966 | 0.79 | GSK3B (0.43) | NAMPTRAB9AHDAC1CYP17A1MAPK1 | |
| SCHEMBL30506468 | 0.79 | DEGS1 (0.48) | NAMPTRAB9AHDAC1CYP17A1MAPK1 | |
| SCHEMBL31726922 | 0.77 | MAPK1 (0.43) | NAMPTRAB9AHDAC1CYP17A1MAPK1 | |
| SCHEMBL16296314 | 0.76 | GSK3B (0.41) | NAMPTRAB9AHDAC1CYP17A1MAPK1 | |
| SCHEMBL28071467 | 0.76 | GSK3B (0.41) | NAMPTRAB9AHDAC1CYP17A1MAPK1 | |
| SCHEMBL18228439 | 0.76 | GPR55 (0.40) | CYP17A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL2214539 | 0.75 | GRIN2B (0.38) | NAMPTHDAC1CYP17A1MAPK1BCL2 | |
| SCHEMBL27946209 | 0.75 | MAPK1 (0.42) | NAMPTHDAC1CYP17A1MAPK1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | NAMPT 341/4885RAB9A 1511/4885HDAC1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.